Literature DB >> 10983652

Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Italian Seroconversion Study.

G Rezza1, M Dorrucci, D Serraino, M Andreoni, M Giuliani, R Zerboni, L Sarmati, V Colangeli, B Salassa, P Monini, B Ensoli, P Pezzotti.   

Abstract

OBJECTIVES: To evaluate temporal trends of Kaposi's sarcoma (KS) and of the KS-related human herpesvirus (HHV-8) among homosexual men who seroconverted for HIV between 1984 and 1997.
METHODS: The study participants were 387 homosexual men. Changes over a period of time were assessed by estimating KS incidence rates per 1000 person-years for the periods 1984-1989, 1990-1992, 1993-1995, and 1996-1997. The proportional incidence of KS as the AIDS-defining disease for the same periods was also calculated. To evaluate a cohort effect of calendar period, Kaplan-Meier curves were used to estimate the risk of KS by period of HIV seroconversion [i.e. before 1990 (median year of seroconversion) versus later]. Relative hazards for the four periods were estimated using competitive-risks models. We also estimated HHV-8 seroprevalence over the study period.
RESULTS: Forty-eight participants developed KS. Between 1984 and 1995, the incidence rate of KS per 1000 person-years increased from 3.9 to 32.8, whereas the proportional incidence decreased from 33.3 to 24.3%. The risk of developing KS after HIV seroconversion did not change when comparing the seroconversion periods (i.e. before 1990 versus later). HHV-8 seroprevalence also remained stable. The rates of KS and the relative hazards dramatically decreased after 1995.
CONCLUSIONS: Although KS incidence rates increased up to 1995, the proportional incidence decreased, due to the higher increase in rates of other AIDS-defining diseases. The finding that the risk of developing KS after HIV seroconversion remained stable over time is consistent with the stable trend of HHV-8 seroprevalence. The dramatic decrease in KS incidence rates after 1995 coincides with combined antiretroviral therapy.

Entities:  

Mesh:

Year:  2000        PMID: 10983652     DOI: 10.1097/00002030-200007280-00021

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  6 in total

1.  Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children.

Authors:  Soren Gantt; Abel Kakuru; Anna Wald; Victoria Walusansa; Lawrence Corey; Corey Casper; Jackson Orem
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

Review 2.  A Review of Human Herpesvirus 8, the Kaposi's Sarcoma-Associated Herpesvirus, in the Pediatric Population.

Authors:  Dorothy E Dow; Coleen K Cunningham; Ann M Buchanan
Journal:  J Pediatric Infect Dis Soc       Date:  2013-09-04       Impact factor: 3.164

3.  Racial and Ethnic Disparities in the Incidence and Trends of Soft Tissue Sarcoma Among Adolescents and Young Adults in the United States, 1995-2008.

Authors:  Mei-Chin Hsieh; Xiao-Cheng Wu; Patricia A Andrews; Vivien W Chen
Journal:  J Adolesc Young Adult Oncol       Date:  2013-09       Impact factor: 2.223

Review 4.  What's new in HIV dermatology?

Authors:  Sarah J Coates; Kieron S Leslie
Journal:  F1000Res       Date:  2019-06-28

5.  Incidence of human herpesvirus 8 (HHV-8) infection among HIV-uninfected individuals at high risk for sexually transmitted infections.

Authors:  Massimo Giuliani; Paola Cordiali-Fei; Concetta Castilletti; Aldo Di Carlo; Guido Palamara; Stefano Boros; Giovanni Rezza
Journal:  BMC Infect Dis       Date:  2007-12-05       Impact factor: 3.090

6.  Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

Authors:  S Franceschi; L Dal Maso; M Rickenbach; J Polesel; B Hirschel; M Cavassini; A Bordoni; L Elzi; S Ess; G Jundt; N Mueller; G M Clifford
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.